Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Leukemia treatment may erase vaccine immunity – study seeks answers

NCT ID NCT07422337

First seen Feb 22, 2026 · Last updated May 22, 2026 · Updated 15 times

Summary

This study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus, hepatitis B, and measles. If protection is low, they will test whether revaccination can restore it. The goal is to create a clear vaccination plan for these patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Arkansas Children's

    RECRUITING

    Little Rock, Arkansas, 72202, United States

    Contact Phone: •••-•••-••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Arkansas Children's Northwest

    RECRUITING

    Springdale, Arkansas, 72762, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.